Education
About Us
Working with TipRanks
Follow Us
XTL Biopharmaceuticals Ltd. (IL:XTLB)
:XTLB
XTLB Stock Chart & Stats
Day’s Range― - ―
52-Week Range3.90 - 11.20
Previous CloseN/A
Volume3.12M
Average Volume (3M)1.08M
Market Cap
52.00M
Enterprise Value13.41M
Total Cash (Recent Filing)2.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding881,385,250
10 Day Avg. Volume1,920,388
30 Day Avg. Volume1,077,836
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
XTLB FAQ
What was XTL Biopharmaceuticals Ltd.’s price range in the past 12 months?
XTL Biopharmaceuticals Ltd. lowest stock price was 3.90 and its highest was 11.20 in the past 12 months.
What is XTL Biopharmaceuticals Ltd.’s market cap?
XTL Biopharmaceuticals Ltd.’s market cap is 52.00M.
When is XTL Biopharmaceuticals Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XTL Biopharmaceuticals Ltd.’s earnings last quarter?
Currently, no data Available
Is XTL Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts XTL Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does XTL Biopharmaceuticals Ltd. pay dividends?
XTL Biopharmaceuticals Ltd. does not currently pay dividends.
What is XTL Biopharmaceuticals Ltd.’s EPS estimate?
XTL Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XTL Biopharmaceuticals Ltd. have?
XTL Biopharmaceuticals Ltd. has 881,385,250 shares outstanding.
What happened to XTL Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of XTL Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IL:XTLB
Company Description
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.